Related Experiment Video
Updated: Jun 24, 2025

Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
Published on: October 6, 2022
Enzyme-free and rapid colorimetric analysis of osteopontin via triple-helix aptamer probe coupled with catalytic
Qin Weng1, Hang Li2, Zhichao Fan3
1School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China; Department of Oncology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, 400038, China.
A new T-CHA biosensor enables rapid, sensitive, and cost-effective detection of osteopontin (OPN), a biomarker for hepatocellular carcinoma (HCC). This portable colorimetric method offers promise for early HCC diagnosis at the point-of-care.
Area of Science:
- Biotechnology
- Biomarker Detection
- Biosensor Technology
Background:
- Osteopontin (OPN) is a key biomarker in hepatocellular carcinoma (HCC) progression.
- Accurate detection of low-abundance OPN is challenging due to limitations of current methods.
- Need for simple, rapid, and sensitive diagnostic tools for HCC is critical.
Purpose of the Study:
- To develop a novel, enzyme-free, colorimetric biosensor for OPN detection.
- To achieve rapid and highly sensitive quantification of OPN in biological samples.
- To provide a cost-effective alternative for HCC diagnostics.
Main Methods:
- Integration of triple-helix aptamer probe (THAP) and catalytic hairpin assembly (CHA) strategy.
- Development of a portable colorimetric biosensor (T-CHA) for visual, label-free detection.
- Quantification via optical density measurement at 650 nm.
Main Results:
- The T-CHA sensor achieved a detection limit of 2.04 pg mL⁻¹ for OPN.
- Linearity was observed for OPN concentrations from 5 pg mL⁻¹ to 5 ng mL⁻¹.
- The T-CHA method is rapid (∼105 min), sensitive, and cost-effective compared to ELISA.
Conclusions:
- The T-CHA strategy offers a promising approach for early HCC diagnosis.
- Successful application in OPN detection in plasma demonstrates clinical potential.
- The T-CHA platform is adaptable for detecting other tumor biomarkers.

